(R)-3-methylhex-5-enoic acid | 128432-05-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (R)-3-methylhex-5-enoic acid
• 英文别名: (3R)-3-Methylhex-5-enoic acid；(3R)-3-methylhex-5-enoic acid
• CAS: 128432-05-3
• 化学式: C₇H₁₂O₂
• 分子量: 128.171
• InChiKey: DUJRYVACNDPJIZ-ZCFIWIBFSA-N

物化性质

• 沸点：
  212.8±9.0 °C(Predicted)
• 密度：
  0.955±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (4R,5S)-1,5-dimethyl-3-[(3R)-3-methylhex-5-enoyl]-4-phenylimidazolidin-2-one 在 lithium hydroxide 作用下， 生成 (R)-3-methylhex-5-enoic acid 、 (4R,5S)-1,5-dimethyl-4-phenylimidazolidin-2-one
  参考文献：
  名称：

  Addition diastéréosélective d'allyl cuprates à des imides chirales insaturées

  摘要：

  DOI：

  10.1016/0022-328x(90)85369-a

文献信息

• Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein
  申请人：Prelude Therapeutics Incorporated

  公开号：US11130769B2

  公开（公告）日：2021-09-28

  The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

  本公开涉及式 I 的化合物 还描述了包含式 I 化合物的药物组合物及其使用和制备方法。
• SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN
  申请人：Prelude Therapeutics, Incorporated

  公开号：EP3877390A1

  公开（公告）日：2021-09-15
• Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein
  申请人：Prelude Therapeutics Incorporated

  公开号：US20200148705A1

  公开（公告）日：2020-05-14

  The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.